Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to undergo its IPO review on September 24, 2025, after a two-year wait on the Sci-Tech Innovation Board, highlighting its progress in the biopharmaceutical sector and its innovative "Thousand Mice Ten Thousand Antibodies" program [1][4]. Group 1: Company Overview - Baiaosaitu was established in 2009 and operates as a preclinical CRO and biotechnology company, providing innovative animal models and drug development services based on its proprietary gene editing technology [1]. - The company has developed the RenMice platform, which allows for large-scale drug discovery targeting nearly a thousand potential drug targets [1]. Group 2: IPO Process and Financial Performance - The company was accepted for its Sci-Tech Innovation Board IPO on June 20, 2023, and has undergone two rounds of inquiries prior to the upcoming review [4]. - Financial data shows that Baiaosaitu's revenue increased from approximately 534 million yuan in 2022 to 980 million yuan in 2024, with a turnaround to a net profit of approximately 33.54 million yuan in 2024 after previous losses [5]. - In the first half of 2023, the company achieved a revenue of 621 million yuan, a 51.27% increase year-on-year, and reported a net profit of approximately 47.99 million yuan, indicating a successful recovery from losses [6]. Group 3: Research and Development Challenges - The company has experienced a significant reduction in its R&D personnel, with the number of dedicated R&D staff dropping from 58 in 2022 to just 5 in 2024, raising concerns about its innovation capacity [7]. - Governance issues are also present, as the major shareholders, who are a married couple, control over 27% of the voting rights, which may impact decision-making processes [7]. Group 4: Fundraising and Strategic Direction - Baiaosaitu has reduced its planned fundraising amount from 1.893 billion yuan to 1.185 billion yuan for its IPO, focusing on early drug development services, antibody drug research, and clinical projects [7][8]. - The company asserts that this reduction in fundraising will not alter its strategic direction, as the core projects will still revolve around its main business and technology platforms [8].

其三，要求发行人代表说明报告期股份支付会计处理是否符合企业会计准则规定。 其一，要求发行人代表结合产品结构、议价能力、市场开拓、主要产品验证及在手订单等情况，说明公 司是否存在毛利率持续下滑风险，以及经营业绩的可持续性。 其二，要求发行人代表说明 Jina Shaw、Ping Xu 及萍妮茹投资、蔡春生及一方建设之间是否存在应披露 未披露的关联关系或一致行动关系。结合实控人持股比例不高、实际控制公司时间较短、公司报告期多 次股权变动、历史上股东之间存在的分歧等情况，说明公司实控人的控制权是否稳定，是否存在上市后 控制权变更风险。 中经记者 孙汝祥 夏欣 实习生 王鑫 北京报道 上交所官网显示，9月19日，上交所上市审核委员会对厦门优迅芯片股份有限公司（以下简称"优迅股 份"）在科创板IPO进行审议，并作出暂缓审议的决定。 根据审议结果公告，上市委会议现场问询了三大问题。 需进一步落实事项为，发行人需说明报告期股份支付会计处理是否符合企业会计准则规定，保荐人和申 报会计师需发表明确核查意见。 （编辑：夏欣 审核：何莎莎 校对：燕郁霞） ...

Core Viewpoint - Xiamen Youxun Chip Co., Ltd. (referred to as "Youxun") has had its IPO on the Sci-Tech Innovation Board postponed for review, raising concerns about its financial sustainability and governance structure [1][2] Group 1: Company Overview - Youxun focuses on the research, design, and sales of optical communication front-end transceiver chips [1] - The company aims to raise approximately 809 million yuan for projects related to next-generation access networks, high-speed data center chips, automotive chips, and 800G and above optical communication chips [1] Group 2: IPO Review Concerns - The listing committee has requested Youxun to address potential risks related to declining gross margins, market expansion, and the sustainability of its operating performance [1] - The committee also inquired about undisclosed relationships among certain investors and the stability of the actual controller's control over the company, given the low shareholding ratio and historical disputes among shareholders [1] Group 3: Financial Reporting - Youxun is required to clarify whether its accounting treatment for share-based payments complies with the relevant accounting standards [2]

9月19日，上交所上市审核委发布公告称，厦门优迅芯片股份有限公司（简称"优迅股份"）科创板IPO暂 缓审议。 据招股书显示，优迅股份专注于光通信前端收发电芯片的研发、设计与销售。公司原计划募资8.89亿 元，冲刺科创板上市。 据了解，优迅股份IPO今年6月26日获受理，7月15日进入问询阶段，此后高效回复两轮问询后进入上会 程序。前期，公司市场空间及成长性、业绩增长可持续性、募投项目、离职员工转让等问题在审核问询 中被重点关注。 从今日的上市委现场问询来看，毛利率持续下滑风险、经营业绩的可持续性，以及实控人的控制权是否 稳定等被重点问询。同时，优迅股份收到一个需进一步落实事项。上市委要求公司说明报告期股份支付 会计处理是否符合企业会计准则规定。 具体来看，上交所要求优迅股份结合产品结构、议价能力、市场开拓、主要产品验证及在手订单等情 况，说明公司是否存在毛利率持续下滑风险，以及经营业绩的可持续性。并请保荐代表人发表明确意 见。 此外，控制权问题再次被监管关注。上交所要求公司说明Jina Shaw、Ping Xu及萍妮茹投资、蔡春生及 一方建设之间是否存在应披露未披露的关联关系或一致行动关系。同时，上交所要求公 ...

Core Viewpoint - Xiamen Youxun Chip Co., Ltd. (referred to as "Youxun") has had its IPO on the Sci-Tech Innovation Board postponed for review, raising concerns about its financial sustainability and governance structure [1][2] Group 1: Company Overview - Youxun focuses on the research, design, and sales of optical communication front-end transceiver chips [1] - The company aims to raise approximately 809 million yuan for the development and industrialization of next-generation access network and high-speed data center chips, automotive chips, and 800G and above optical communication chips and silicon photonic components [1] Group 2: IPO Review Concerns - The listing committee has requested Youxun to address potential risks related to declining gross margins, market expansion, and the sustainability of its operating performance [1] - The committee also inquired about undisclosed related party relationships among certain investors and the stability of the actual controller's control over the company, given the low shareholding ratio and historical ownership changes [1] Group 3: Accounting Compliance - Youxun is required to clarify whether its accounting treatment of share-based payments during the reporting period complies with the relevant accounting standards [2]

见微知著 睹始知终 V财网&小V研究 值得一提的是，优迅股份由厦门大学校友柯炳粦创立。该公司 IPO 申请于今年 6 月 26 日正式获受理，从申请获受理到进入上会审议阶段，间隔不足 3 个 月，进程相对迅速。此次冲击科创板，优迅股份计划募集资金 8.09 亿元，所筹资金将主要投入三大项目，分别是下一代接入网及高速数据中心电芯片开发 及产业化项目、车载电芯片研发及产业化项目，以及 800G 及以上光通信电芯片与硅光组件研发项目。 然而，尽管优迅股份有着 "光通信单项冠军" 的头衔，但其业绩表现却未达市场预期，甚至未能满足科创板属性中 "最近三年营业收入复合增长率需达到 25%" 的指标要求。招股书数据显示，2022 年至 2024 年，优迅股份营业收入分别为 3.39 亿元、3.13 亿元、4.11 亿元；同期净利润分别为 8139.84 万元、 7208.35 万元、7786.64 万元。从这两组核心业绩数据不难看出，优迅股份在营业收入和净利润这两大关键业绩指标上，并未展现出科创类公司应有的强劲 成长性。 除此之外，报告期内，优迅股份主营业务毛利率呈明显下滑趋势。具体来看，各期毛利率分别为 55.26%、4 ...

Group 1 - The core point of the article is that Changjin Photon Technology Co., Ltd. has entered the inquiry stage for its IPO on the Sci-Tech Innovation Board [1] - Changjin Photon is a manufacturer of specialty optical fibers, with capabilities in high-performance and multi-category specialty optical fiber research and industrialization [1] - The company aims to raise approximately 780 million yuan through the IPO, which will be used for the construction of a high-performance specialty optical fiber production base and research center, as well as to supplement working capital [1]

Group 1 - The core point of the article is that Xiamen Hengkang New Materials Technology Co., Ltd. has successfully registered its IPO on the Sci-Tech Innovation Board [1] - The company focuses on the research and industrial application of key materials in the integrated circuit field, specifically in the development, production, and sales of photoresist materials and precursor materials [1] - The IPO process began with acceptance on December 26, 2024, followed by an inquiry phase starting on January 18, 2025, and approval on August 29, 2025, with registration submitted on the same day [1] Group 2 - Hengkang New Materials aims to raise approximately 1.007 billion yuan through this IPO, which will be allocated to the second phase of the integrated circuit precursor project and advanced materials for integrated circuits, after deducting issuance costs [1]

Core Viewpoint - Xiamen Youxun Chip Co., Ltd. (Youxun Co.) is rapidly advancing its IPO process, with the listing review committee meeting scheduled for September 19, 2025, just under three months after its application was accepted on June 26, 2025 [1][3]. Company Overview - Youxun Co. was established in February 2003 and specializes in the research, design, and sales of optical communication front-end transceiver chips, which are primarily used in optical modules across various applications including access networks, 4G/5G networks, data centers, metropolitan area networks, and backbone networks [3]. - The company aims to raise 889 million yuan (approximately 8.89 billion yuan) through its IPO, with plans to invest in the development and industrialization of next-generation access network and high-speed data center chips, automotive chips, and 800G and above optical communication chips [3]. Financial Performance - From 2022 to 2024, Youxun Co.'s revenue decreased from 339 million yuan to 313 million yuan, before rebounding to 411 million yuan. Net profit also saw a decline from 81.4 million yuan to 72.08 million yuan, followed by a recovery to 77.87 million yuan [4]. - In the first half of 2023, the company's revenue grew by 20.19% year-on-year, while major downstream customers experienced revenue growth exceeding 50% [4]. - Despite the revenue recovery, the company's gross margin has been declining, with figures of 55.26%, 49.14%, 46.75%, and 43.48% for the respective years from 2022 to the first half of 2025 [4][5]. R&D and Cost Structure - Youxun Co.'s R&D expense ratio decreased from 21.14% in 2022 to 15.81% in the first half of 2025, which is below the industry average during the same period [5]. - The decline in gross margin is attributed to changes in industry demand, price reductions of key products, and rising costs of certain procurement items [5]. Shareholding and Control - The company has undergone two changes in its actual controller since its establishment, with the current controllers, Ke Binglan and Ke Tenglong, holding a combined voting power of 27.13% prior to the IPO. Post-IPO, this is expected to dilute to 20.35% [6]. - The current actual controllers lack technical development backgrounds, with Ke Binglan previously involved in financing and management roles [6][7].

Core Viewpoint - Xiamen Hengkang New Materials Technology Co., Ltd. has received approval for its IPO on the Sci-Tech Innovation Board, but faces significant challenges due to high customer concentration and a notable disparity between revenue growth and profit decline [1][2][4]. Group 1: Revenue and Profitability - Hengkang New Materials has shown strong revenue growth with a compound annual growth rate of 30.5%, but struggles with profitability, as evidenced by a 25.18% decline in net profit in the first half of 2025 despite a 23.74% increase in revenue [1][2][3]. - The company’s revenue heavily relies on its top five customers, which accounted for over 97% of total sales during the reporting period, indicating a high customer concentration risk [3][4]. - The revenue figures for 2022 to 2024 show a significant increase, with 2024 revenue up 70.29% compared to 2022, yet net profit decreased by nearly 3 million [2][3]. Group 2: Customer Dependency - The largest customer contributed 64% of total revenue in the lowest year of the reporting period, raising concerns about the sustainability of the business model if relationships with key clients deteriorate [4][5]. - The company’s reliance on a few key customers poses a risk to its operational performance, as any changes in these relationships could adversely affect financial results [4]. Group 3: Product Profitability - Hengkang New Materials has a dual product structure, with self-produced products and introduced products, but the latter remains the primary source of profit, contributing over 65% of gross profit despite a growing share of self-produced products in revenue [5][6]. - The gross profit margins for self-produced products have been declining, falling below industry averages since 2023, raising questions about their technological competitiveness [9]. Group 4: IPO Fund Utilization and Project Viability - The company plans to raise 1.007 billion yuan for expansion projects, including the second phase of integrated circuit precursors and advanced materials, but the rationale behind these projects is under scrutiny due to ongoing losses in precursor products [1][10][12]. - The utilization rates for KrF photoresist production have been alarmingly low, with rates below 20%, leading to skepticism about the decision to expand production capacity in this area [12].